-

STERICYCLE, INC. INVESTIGATION ALERT REMINDER: Scott+Scott Attorneys at Law LLP Continues to Investigate Stericycle, Inc.’s Directors and Officers for Breach of Fiduciary Duties – SRCL

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, reminds investors it is investigating whether certain directors and officers of Stericyle, Inc. (“Stericycle”) (NASDAQ: SRCL) breached their fiduciary duties to Stericycle and its shareholders. If you are a Stericycle shareholder, you are encouraged to contact attorney Joe Pettigrew with Scott+Scott for additional information at (844) 818-6982 or jpettigrew@scott-scott.com.

Scott+Scott is investigating whether members of Stericycle’s board of directors or senior management failed to manage Stericycle in an acceptable manner, in breach of their fiduciary duties to Stericycle, and whether Stericycle and its shareholders have suffered damages as a result.

On April 20, 2022, it was announced that Stericycle agreed to pay over $84 million to resolve parallel investigations by U.S. and Brazilian regulators regarding bribery of foreign officials in Brazil, Mexico, and Argentina from 2011-2016.

What You Can Do

If you are a Stericycle shareholder, you may have legal claims against Stericycle’s directors and officers. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at (844) 818-6982 or jpettigrew@scott-scott.com.

About Scott+Scott Attorneys at Law LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and consumer rights actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, and Ohio.

Attorney Advertising

Contacts

Joe Pettigrew
Scott+Scott Attorneys at Law LLP
600 W. Broadway, Suite 3300, San Diego, CA 92101
(844) 818-6982
jpettigrew@scott-scott.com

Scott+Scott Attorneys at Law LLP

NASDAQ:SRCL

Release Versions

Contacts

Joe Pettigrew
Scott+Scott Attorneys at Law LLP
600 W. Broadway, Suite 3300, San Diego, CA 92101
(844) 818-6982
jpettigrew@scott-scott.com

More News From Scott+Scott Attorneys at Law LLP

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Hub Group, Inc. (NASDAQ: HUBG)

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Hub Group, Inc. (“Hub Group” or the “Company”) (NASDAQ: HUBG) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws. CLICK HERE TO RECEIVE ADDITIONAL INFORMATION ABOUT THIS POTENTIAL CLASS ACTION Hub Group is a transport...

Scott+Scott Attorneys at Law LLP Files Securities Class Action Against PomDoctor, Ltd. (NASDAQ: POM)

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, today announced that it has filed a class action lawsuit against Defendants PomDoctor Ltd., Zhenyang Shi, Li Xu, Cogency Global, Joseph Stone Capital, LLC, and Marcum Asia CPAs, LLP (collectively, the “Defendants”). The action, which was filed in the U.S. District Court for the Southern District of New York and captioned Louie v. PomDoctor Ltd. et al., Ca...

ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company’s Directors and Officers for Breach of Fiduciary Duties – LLY

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the leadership of Eli Lilly and Company (“Eli Lilly”) (NYSE: LLY) breached their fiduciary duties to Eli Lilly and its shareholders. CLICK HERE TO LEARN MORE Scott+Scott is investigating whether members of Eli Lilly’s board of directors or senior management failed to manage Eli Lilly in an acceptable manner, in breach of their fid...
Back to Newsroom